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Abstract
Background: We have previously described fundamental differences in the biology of stem cells as compared to other
dividing cell populations. We reasoned therefore that a differential screen using US Food and Drug Administration (FDA)-
approved compounds may identify either selective survival factors or specific toxins and may be useful for the
therapeutically-driven manufacturing of cells in vitro and possibly in vivo.
Methodology/Principal Findings: In this study we report on optimized methods for feeder-free culture of hESCs and hESC-
derived neural stem cells (NSCs) to facilitate automated screening. We show that we are able to measure ATP as an indicator
of metabolic activity in an automated screening assay. With this optimized platform we screened a collection of FDA-
approved drugs to identify compounds that have differential toxicity to hESCs and their neural derivatives. Nine compounds
were identified to be specifically toxic for NSCs to a greater extent than for hESCs. Six of these initial hits were retested and
verified by large-scale cell culture to determine dose-responsive NSC toxicity. One of the compounds retested, amiodarone
HCL, was further tested for possible effects on postmitotic neurons, a likely target for transplant therapy. Amiodarone HCL
was found to be selectively toxic to NSCs but not to differentiated neurons or glial cells. Treated and untreated NSCs and
neurons were then interrogated with global gene expression analysis to explore the mechanisms of action of amiodarone
HCl. The gene expression analysis suggests that activation of cell-type specific cationic channels may underlie the toxicity of
the drug.
Conclusions/Significance: In conclusion, we have developed a screening strategy that allows us to rapidly identify clinically
approved drugs for use in a Chemistry, Manufacture and Control protocol that can be safely used to deplete unwanted
contaminating precursor cells from a differentiated cell product. Our results also suggest that such a strategy is rich in the
potential of identifying lineage specific reagents and provides additional evidence for the utility of stem cells in screening
and discovery paradigms.
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Introduction
The ability to expand human embryonic stem cells (hESCs)
unlimitedly in culture and to differentiate them into specific
somatic cell types [1] make them a useful tool in the development
of hESC-based automated screening platforms for drug discovery.
Although this possibility has not yet attracted as much attention as
the ideas of cell replacement, personalized medicine and other
more direct clinical applications, hESCs are expected to be
superior to most commonly used cell-culture models of drug
discovery which employ tumor-derived or immortalized cell lines
or primary cell culture. This is because tumor-derived and
immortalized cells are often karyotypically abnormal and may
diverge physiologically from normal cells in various respects,
whereas primary cells have limited capacity for expansion.
To enable the development of hESC-based automated
screening, it is essential that current limitations surrounding hESC
culture be overcome. For example, hESCs and their differentiated
derivatives must be cultured without feeder layers in a format that
is amendable to automated screening such as 96 well plates. Unlike
mouse embryonic stem cells which can be efficiently expanded and
differentiated from single cells, hESCs are routinely passaged as
small clumps of cells or differentiated via embryoid bodies formed
from tens to hundreds of cells [1]. The recent advances in
culturing hESCs in defined media [2,3,4] and the report of
increased cloning efficiency of hESCs [5] make it possible to
develop protocols for culturing hESCs in large numbers.
Nevertheless, feeder-free culturing of hESCs is not a routine
success. Excellent outcomes notwithstanding, hESC-based screen-
ing platforms are limited by the difficulties of generating
PLoS ONE | www.plosone.org 1 September 2009 | Volume 4 | Issue 9 | e7155homogeneous and lineage-specific differentiated populations from
hESCs while culturing them in large numbers for prolonged
periods.
Given our extensive experiences in neuronal differentiation of
hESCs [6,7,8] and the potential application of hESC-derived
neurons in cell replacement therapies for neurodegenerative
diseases, we designed a set of experiments aimed at developing a
hESC-based automated assay for screening small molecules that
have differential toxicity to hESC-derived NSCs and their
differentiated neural progenies. We reasoned that the development
of this assay would help identify chemical compounds that may be
useful for eliminating proliferating cells in potential hESC-derived
cell therapy products. To this end, we chose to use the National
Institute of Neurodegenerative Diseases and Stroke (NINDS)
collection of FDA-approved drugs for assay optimization and pilot
screening. The bioactivity of the compounds in this library and the
ready availability of individual compounds identified as hits for
follow-up studies make this library ideal for pilot screenings.
Furthermore, these routinely used drugs have been highly
optimized to hit specific targets and in nearly all cases the
mechanisms of action are known.
By comparative screening on hESCs and hESC-derived
homogenous NSCs using the NINDS collection, we were able to
identify compounds that had differential toxicity to both cell
populations. Hits obtained in the primary screen were then
retested and a small subset was assayed for dose-responsiveness.
One confirmed dose-responsive compound, amiodarone HCl, was
further tested for toxicity in postmitotic neurons. We found
amiodarone HCL to be toxic to NSCs but not to postmitotic
neurons, indicating its potential use for depleting proliferating
NSCs in hESC-derived cell populations for possible neural
transplantation.
Materials and Methods
Culturing of hESCs and hESC-derived NSCs
hESC lines I6 and H9 were maintained on Matrigel (BD
Biosciences, Bedford, MA; http://www.bdbiosciences.com)coated
dishes in medium (comprised of Dulbecco’s Modified Eagle’s
Medium/Ham’s F12 supplemented with 20% knockout serum
replacement (KSR), 2 mM non-essential amino acids, 4 mM L-
glutamine, 0.1 mM b-mercaptoethanol, 50 mg/ml Penn-Strep,
and 4 ng/ml of basic fibroblast growth factor) conditioned with
mouse embryonic fibroblasts for 24 hours as previously described
[9,10].
To derive NSCs as previously described [11], hESC colonies
were harvested using a scraper and cultured in suspension as EBs
for 8 days in ESC medium minus FGF2. EBs were then cultured
for additional 2–3 days in suspension in neural induction media
containing DMEM/F12 with Glutamax, 1 xNEAA, 1 xN2 and
FGF2 (20 ng/ml) prior to attachment on cell culture plates.
Numerous neural rosettes were formed 2–3 days after adherent
culture. To obtain a pure population of NSCs, rosettes were
manually isolated and dissociated into single cells using Accutase.
The NSCs population was expanded in Neurobasal media
containing 1x NEAA, 1x L-Glutamine (2 mM), 1x B27, LIF and
FGF2 20 ng/ml.
Dopaminergic neuronal differentiation of hESC-derived NSCs
was induced by medium conditioned on the PA6 stromal cell line for
4 weeks [12]. The media contained GMEM with 10%KSR, 1x non-
essential AA, 1x Na pyruvate and 1x b-mercaptoethanol and was
harvested from the PA6 culture every 24 h for a period of 1 week.
Human astrocytes were purchased from Sciencell Research
Laboratories (isolated from human cerebral cortex, Cat# 1800,
Carlsbad, CA) and were cultured in human astrocyte medium
(Sciencell, Cat# 1801) on poly-L-lysine coated tissue culture
dishes. Media was changed every other day and cells were
passaged once a week at a 1:4 ratio.
2102Ep cells, derived from a primary human testicular
teratocarcinoma and later subcloned [13] (ATCC) were grown
on tissue culture dishes in medium containing DMEM supple-
mented with 2 mM Glutamax and 10% fetal bovine serum. Media
was changed every day and cells were passaged every 3–4 days at a
ratio of between 1:4 to1:6.
Drug Treatment and ATP assay
hESCs and NSCs were passaged onto 96 well plates at a density
of 5610
4 and 2.6610
4 cells respectively in 200 ml media and
incubated at 37uC for 48 hours. Media was changed every day for
hESCs and every other day for NSCs and additionally changed
prior to drug treatment. The cells were treated with compounds
from the NINDS library diluted in 100 ml of either ESC or NSC
media to a final concentration of 2.5 mM in 0.01% DMSO. Cells
were incubated in the presence of drug for an additional 48 hours
at 37uC before assaying. For all sampling, ESC and NSC plates
were processed in parallel for one drug or control condition at a
time.
For ATP measurements, the media was removed, cells were
washed 1x in milliQ water and reconstituted in 50 mL ATP-Lite
Mammalian Lysis Buffer and shaken for 5 minutes. Two 10 mL
aliquots of lysed cells were replated onto separate 96 well plates for
later protein measurements.
For measuring the effect of TNFa on NSCs, I6 NSCs were
passaged onto fibronectin-coated 4-well plates in Neurobasal
media supplemented with 1X B27, 2 mM L-glutamine and
10 ng/ml of both bFGF and LIF growth factors. Cells were
recovered for 12 hours at 37u and then either left untreated or
treated with solTNFa at the concentrations indicated. Cultures
were observed for 24 hours after solTNFa treatment for signs of
cell death and imaged with microscopy.
Immunocytochemistry
Immunocytochemistry and staining procedures were as de-
scribed previously [14]. Briefly, hESCs at different stages of
dopaminergic differentiation were fixed with 2% paraformalde-
hyde for half an hour. Fixed cells were blocked for one hour in
0.1% Triton X-100 PBS supplemented with 10% goat serum and
1% BSA, followed by incubation with the primary antibody at 4uC
overnight in 0.1% Triton X-100 with 8% goat serum and 1%
BSA. Appropriately coupled secondary antibodies (Molecular
Probes) were used for single and double labeling. All secondary
antibodies were tested for cross reactivity and non-specific binding.
The following primary antibodies were used: Oct-4 (19857
Abcam) 1:1000; b-III tubulin clone SDL.3D10 (T8660 Sigma)
1:500; Nestin (611658 BD Transduction laboratories) 1:500 and
TH (P40101 Pel-Freez) 1:500, and as secondary antibodies: Alexa
Fluor 594 Goat Anti-Mouse, Alexa Fluor 488 Goat Anti-Rabbit,
Alexa Fluor 594 Goat Anti-Rabbit. Hoechst 33342 (Molecular
Probes H3570) 1:5000 was used for nuclei identification. Images
were captured on a Nikon fluorescence microscope.
Microarray analysis using BeadArray platform
RNAs isolated from NSCs and neurons with and without drug
treatments were hybridized to Illumina HumanRef-8 BeadChip
(Illumina, Inc., San Diego, CA, performed by Microarray core
facility at the Burnham Institute for Medical Research). The
Illumina array data were normalized by the quantile method, and
then transformed log2 ratio values for a zero mean for expression
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bioinformatics analyses were conducted by using R and the
bioconductor package (www.bioconductor.org). The gene set
enrichment analysis was conducted using the GSEA software
(www.broad.mit.edu/gsea).
Results
Culturing of multiple hESC and hESC-derived NSC lines in
96-well plates
We have previously shown that NSCs can be generated from
multiple hESC lines and can be cultured for prolonged periods
without losing their ability todifferentiate intoneurons, astrocytesand
oligodendrocytes [11]. The hESC lines H9 and I6 and their NSC
derivatives behave similarly in culture and were used for this study.
For adapting to a 96-well format culture, hESCs were
dissociated into single cells by Accutase. Tiny colonies were
formed 24 h after plating (Fig. 1A) and typical undifferentiated
hESC morphology was observed 2–3 days after passage (Fig. 1B).
No differences in the expression of the pluripotent marker Oct4
(Fig. 1C–D) were found between cells cultured in 96-well plates
and hESCs routinely passaged in medium conditioned on MEF in
larger dishes (35-mm or 60-mm dishes). NSCs cultured in 96-well
plates were morphologically indistinguishable from cells cultured
in larger dishes (Fig. 1E–F) and uniformly expressed the NSC
specific marker Nestin (Fig. 1G–H).
Screening design, primary screening and retest of hits
To identify compounds that are toxic to hESCs, hESC-derived
NSCs, or both, we screened 720 FDA-approved drugs of the
NINDS collection by testing the toxicity of each drug at a dose of
2.5 mM. For endpoint measurement of cell death caused by drug
toxicity, we used a widely accepted ATP assay that measures
changes in ATP level as an indicator of cellular response to cell
death. In this assay, total ATP content per well was measured and
normalized to the total cellular protein.
In general, NSC-containing wells had much higher ATP levels
than the hESC wells (Fig. 2A, standard deviation for variance in
each plate provided in Supplementary Materials Table S4),
consistent with recent reports that ATP levels are higher in
differentiated EBs than in undifferentiated hESCs [15]. Hits were
defined based on the ability of a compound to affect ATP levels
relative to DMSO controls on each plate. Nine compounds,
pirenzepine HCL, amiodarone HCL, selamectin, clofoctol,
perhexilline maleate, griseofulvin, chloroactoxyquinoline, mena-
dione and hexetidine were identified as ‘‘NSC Killers’’ in this
primary screen. Application of these nine drugs reduced ATP
concentrations with at least 2-fold or more potency for NSCs than
hESCs, and NSC values were 15% or more below the control
mean. In contrast, no compound was found to be specifically toxic
to hESCs based on the same criteria.
We then retested the nine hits from the NINDS library screening
in 96-well plates. Three concentrations of each compound (1 mM,
2.5 mMa n d1 0 mM) were used in the retest. Six of the nine
compounds, amiodarone HCL, selamectin, chloroacetoxyquino-
line, menadione, pirenzepene and clofoctol showed a dose-
dependent specific toxicity as demonstrated by reduced ATP
concentrations in treated NSCs versus untreated NSCs, untreated
hESCs and treated hESCs (Fig. 2B). Notably, of these 6 compounds
that demonstrated dose responsive toxicity to NSCs, selamectin and
amiodarone HCL had the most dramatic effect on NSC survival
(Fig. 2B, p,0.001 for amiodarone HCL treated NSC versus
similarly treated ESC, N=3 independent replicates). Overall, these
results indicate that changes in ATP levels are a reliable indicator of
cell death in stem cell populations upon drug insults and may have
utility for hESC-based automatic screening assays.
Revalidation in larger numbers of cells and behavior of a
candidate molecule on postmitotic neurons
For potential hESC-based neural replacement therapy, it would
be useful to identify compounds that are selectively toxic to
proliferating NSCs and not terminally differentiated postmitotic
neurons. We therefore decided to interrogate the effects of one
retested compound, amiodarone HCl, on NSCs and their
differentiated derivatives. For postmitotic neurons, we chose to
use an established neuronal differentiation culture system in which
NSCs were induced to differentiate into dopaminergic neurons by
medium conditioned on stromal cells for 4 weeks. After 4 weeks of
differentiation, the majority of the cells (.60%) expressed the
postmitotic neuronal marker b-III tubulin with a subset (about
50% of total neurons) additionally expressing TH, a marker for
midbrain dopaminergic neurons (Fig. 3A–D). Less than 1% of the
cells were positively stained for Sox1, a marker for NSCs (data not
Figure 1. Morphology and expression of stem cell markers in
hESCs and hESC-derived NSCs cultured in 96-well plates. (A–B)
Typical undifferentiated hESC morphology 24 hours after plating (A)
and 3 days after passaging (B). (C–D) Expression of pluripotent markers
Oct4 in cells cultured in 96-well plates (C, Oct4=green, nuclei=blue)
and colonies cultured in 60 mm dishes (D, Oct4=red, nuclei=blue). (E–
F) Homogenous hESC-derived NSCs are morphologically similar
whether cultured in 96 well plates (E) or larger 60 mm dishes (F). (G–
H) Uniform expression of nestin in NSCs cultured in 96 well plates (G)
and 60 mm dishes (H) Nestin=red, nuclei=blue.
doi:10.1371/journal.pone.0007155.g001
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PLoS ONE | www.plosone.org 3 September 2009 | Volume 4 | Issue 9 | e7155Figure2.PrimaryscreensandretestswiththeNINDScollection.(A)ATPlevelsinhESCsandNSCs.(B)DoseresponseofNSCandhESCtoselectively
screened NINDS compounds. Hits obtained in the primary screen were retested and validated to be toxic to NSCs in a dose-responsive manner.
doi:10.1371/journal.pone.0007155.g002
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in this study.
NSCs and dopaminergic neurons grown in 35-mm dishes were
exposed to amiodarone HCl. Cell death was observed in NSCs
2 hours after drug exposure, with more than 90% cell death evident
by 8 hours (Fig. 3E–G). In contrast, no toxic effect was observed in
dopaminergic neurons up to 8 hours after exposure to amiodarone
HCl (Fig. 3H-J) at the highest dose (10 mM). At 10 mM, amiodarone
HCL reduced ATP levels to less than 15% of the control mean
specifically in the NSC population (Fig. 3K). In contrast, at this
concentration amiodarone HCL was not toxic to dopaminergic
neurons. Interestingly, the effect seen in hESC was intermediate
between NSCs and dopaminergic neurons. To confirm the
specificity of effect of amiodarone treatment on NSCs and rule out
the possibility that the different media contributed to the protection
seen for dopaminergic neurons, we derived neurons in defined
media [11] and treated them with amiodarone HCL. Like neurons
derived by PA6 conditioned medium, neurons generated in defined
media were not susceptible to amiodarone toxicity (data not shown).
Effects of amiodarone HCl on glia (non-neuronal) cells
To further confirm the specificity of amiodarone HCl ’s toxicity
on NSCs but not cells differentiated from NSCs, we tested the
effect of amiodarone HCl on human fetal-derived astrocytes [16],
Figure 3. Validation of a compound in larger numbers of cells. (A–D) Expression of b-III tubulin (A, red) and TH (B, green) in NSCs that had
been differentiated for 4 weeks (C=nuclei, blue, D=merge). (E–G) NSCs after 2 (E), 4 (F) and 8 (G) hours exposure to amiodarone HCl (H–J)
dopaminergic neurons after 2 (H),4 (I) and 8 (J) hours exposure to amiodarone HCl. (K) Changes in ATP levels in hESC (blue line), NSC (pink line) and
dopaminergic neurons (yellow line) after exposure to three doses of amiodarone HCl for 48 h (at 10 um NSC v DA p,0.001, N=3 replicates)
doi:10.1371/journal.pone.0007155.g003
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amiodarone HCl did not cause astrocyte cell death up to 48 hours
after treatment, whereas once again massive cell death occurred in
similarly treated NSCs within one hour of drug administration. As
an additional control we also tested the effect of amiodarone HCl
on an immortal cell line 2102Ep cells [13]. Like terminally
differentiated dopaminergic neurons and astrocytes, no effect was
found on 2102Ep cells 48 hours after treatment (data not shown).
Pathways activated by amiodarone HCl
In order to validate that the observed cell death was specific to
the action of amiodarone HCL, and possibly dissect the
mechanism of action of this compound, we performed a gene
expression analysis of NSCs and postmitotic neurons receiving
amiodarone HCL. Given that changes in gene expression profiles
will likely be seen after a short period exposure to drugs, and that
most cells had undergone cell death in as little as 8 hours (Fig. 3E–
G), we compared gene expression of cells prior to and after
4 hours of exposure to the drugs. The dataset generated from the
expression analysis, along with quality control data and the
numbers of genes altered are provided in Supplementary Table 1
(Table S1) and Supplementary Fig. 1 (Figure S1).
Gene Set Enrichment Analysis (GSEA) was conducted to
identify pathways, biological process and molecular functions that
are enriched in genes differentially expressed by NSCs or
dopaminergic neurons treated with amiodarone HC. In this
method, all the genes are ranked according to the differential
expression between two classes, and the Kolmogorov-Smirnoff test
is used to determine the statistical correlation of the ranked gene
list to the gene set of a given biological process, pathway or
molecular function. The comparative results are then measured by
a non-parametric, running sum statistic termed the enrichment
score. The enrichment score significance is assessed by 1,000
permutation tests to compute the enrichment p-value. Supple-
mentary Table 2 (Table S2) lists the pathways, biological process,
and molecular functions that are significantly enriched (P
value,0.05) in differentially expressed genes between drug-treated
NSCs and non-treated NSCs. Supplementary Table 3 (Table S3)
lists the pathways, biological process, and molecular functions that
are significantly enriched (P value,0.05) in differentially expressed
genes between drug-treated dopaminergic neurons and untreated
populations. As shown in Supplementary Figure 2 (Figure S2),
GSEA analysis revealed that cation channel activity was higher in
both cohorts of untreated NSCs and dopaminergic neurons, while
Figure 4. Effect of amiodarone HCl on glia cells. Human Astrocytes (HA, top panel) after 1, 26 and 48 hours exposure to amiodarone HCl and
untreated cells. NSCs, either after 1, 2, 3 and 4 hours exposure to amiodarone HCl or left untreated are shown on the bottom panel for comparison.
doi:10.1371/journal.pone.0007155.g004
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dopaminergic neurons.
Category Gene Treated NSC Untreated NSC Treated DA Neuron Untreated DA Neuron
H ion transporters ATP6V1A 1155.9 1093.8 2621.5 2441.8
ATP6V1B2 385.4 331 724.8 438.2
ATP6V0D1 3355 2760.4 2920.7 2452.5
ATP5B 7030.3 5745.1 5217.1 4313.4
ATP6V0A2 190.2 163 131.3 108
SLC2A11 22.8 31.1 .9 34.9
SLC35B1 1769.8 1380.4 1450.4 1122.8
SLC2A1 1274.8 1574.5 87.1 86.7
Amine transporters SLC1A2 15.7 21.3 809.7 681
SLC1A3 552.1 433.5 2926 2578.1
SLC6A3 21.2 4.8 23.4 10.5
SLC6A9 329.2 251.5 36570.5 489.3
SLC6A12 9.6 7.4 10.8 10.4
ATP1A1 586.9 615.7 426.9 341.4
ATP1A1 786.4 725.1 471 399.4
Cl channels CLCN6 349.8 311.8 998.5 745.9
CLCN7 1305.5 903.2 1261 1058.4
CLCN3 566.5 440.4 541.2 497.2
CLCN2 41.6 30.2 24 21.7
CLIC1 122.2 94.9 22.9 18
Voltage gated Na channels SCN9A 1.9 2.6 245.7 175.1
SCN1A 20.5 7.6 115.6 110.2
SCN3A 5.7 6.3 60.4 72.3
Amiloride sensitive Na channels ACCN1 16.5 15.4 387.4 360.1
ACCN3 11 5.1 35.7 38.1
ACCN2 185.7 167.4 862.7 837.1
Rectifier K channels KCND2 2.3 8.9 269.9 225.5
KCNQ2 138.1 137 1753.5 1378.2
KCNC4 4.5 5.8 58.7 38.7
KCNJ4 15.9 11.6 66.1 64.3
KCNQ3 3.4 5.5 23.2 25.4
KCNG1 150.4 92.7 351 365
KCNF1 189.2 152 479.7 457.6
KCNJ11 13.5 17.7 44.4 26.5
KCNJ6 317.3 271.5 297.7 256.7
KCNQ2 919.6 796.2 434.4 420.4
Delayed rectifier K channels KCNA5 24.2 0.4 99.9 84
KCNS1 5.2 2.2 20.3 39.9
KCNH2 25.6 32 165.6 151.9
KCNB1 32.8 34.2 145.4 111.5
KCNB2 25 28.7 94.5 79.1
KCNH2 11.2 5.8 21 14.2
Ca activated K channels KCNN1 6.5 0.6 48.4 28.9
KCNN3 0.7 6.3 181.7 127.1
KCNN2 15.8 12.3 55.6 50.1
KCNMB1 62.9 60.4 44.8 72.6
Calcium channels CACNB2 7.8 12 155.2 156.9
CACNG2 2.5 11.5 123.8 115.6
CACNA1A 2 10.1 64.4 62.6
hESC-Based Drug Screening
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S2A). We noted that the tumor necrosis factor receptor 2 (TNFR2)
pathway and neurogenic pathways were enriched in drug-treated
NSCs (P value,0.035, Fig. S2B-E), but the two pathways were not
enriched in NSCs and dopaminergic neurons prior to drug
treatment. These results in their aggregate suggest that cationic
channels, TNFR2-related pathways and neurogenic pathways may
have important implications in the response of NSCs to
amiodarone HCL drug treatment.
Based upon the GSEA results, we wanted to test our hypothesis
that amiodarone HCL toxicity may act via specific cationic
channels. We reasoned that a higher basal expression level of
cation channels would render cells more susceptible to the channel
blocking effect of amiodarone HCL seen in the GSEA data. Indeed,
the role of amiodarone HCL in blocking multiple cation channels
has been previously described [17,18,19,20,21,22,23,24,25]. To
interrogate the susceptibility of both NSCs and dopaminergic
neurons to amiodarone HCL-induced channel blocking, we
examined differences in the expression of ion channels in both
NSCs and dopaminergic neurons (Table 1). Comparison of gene
expression profiles indicate that both the SLC2A1 and CLICl
receptor subunit transcripts are expressed at significantly higher
levels in NSCs but not in differentiated neurons, suggesting that
NSCs may be more sensitive to the channel-effects of amiodarone
HCL. Interestingly, published reports show that hESCs, which are
intermediately affected by treatment withamiodarone HCLrelative
to NSCs and DA neurons (Fig. 3K), express SLC2A1 at higher
levels than DA neurons, but less than the expression seen in NSCs
(expression levels of 317 and 103.2 from two independent lines of
BGO1, sample 131 and 122, respectively, seen in [26] ).
The TNFR2 pathway, also identified in the GSEA analysis as
being selectively enriched in NSCs treated with amiodarone HCL
(Fig. S2B–C), has been shown to trigger cellular apoptosis [27]. To
elucidate the downstream activators of cell death in the
amiodarone HCL-treated samples, we sought to examine
transcription factors that were either activated or repressed four
hours after exposure to the drug. To be more specific, we searched
for transcription factors that were changed in NSCs after exposure
to amiodarone HCl but showed no change in differentiated cells
after treatment with equivalent amounts of the drug. Supplemen-
tary Table 5 lists the transcription factors. As can be seen in Table
S5, amiodarone HCL treatment in NSCs significantly up
regulated Fos, FosB, and DDIT3, transcription factors known to
participate in TNFa receptor-mediated apoptosis through forma-
tion of the DNA-binding complex AP-1 [28,29,30,31]. Notably,
genes thought to induce and promote apoptosis through the
intrinsic mitochondrial apoptotic pathway, such as KLF10 [32],
were not altered in differentiated cells or in treated versus
untreated cells. Since amiodarone HCL is known to exert its
cytotoxic effect through the extrinsic, caspase-9 independent
apoptotic pathway [33] our microarray results confirm that the
differential cytotoxic effect seen in NSCs treated with amiodarone
HCL is due to specific activation of extrinsic apoptosis pathways
resulting from exposure to the drug.
Our microarray data showed a number of genes in the TNFa
pathway were highly expressed in amiodarone HCl-treated NSCs.
We therefore examined whether cell death in NSCs upon
amiodarone HCl exposure could be due to the activation of
soluble TNFa signaling pathways. Three dosages of soluble TNFa
(0.1 mM, 1 mM and 10 mM) were tested in NSC culture for
48 hours. Under these conditions we did not observe differences in
cell death between treated and untreated cells (Fig. 5).
Discussion
Our screening approach provides a new platform technology for
using hESCs and purified populations of their differentiated neural
derivatives to rapidly screen and identify compounds that exert
specific effects on these cell types. This screening approach relies
on the observable phenotype of cell death coupled with gene
expression analysis to identify pathways of cell-type specific drug
activity. To extend its utility, this approach can also provide clues
to the molecular mechanisms that participate in stage-specific
cytotoxic effects of candidate drugs. We had reasoned that because
of fundamental differences in cell cycle and growth factor
dependence, there would likely be drugs that were specific to
one cell type versus another. Indeed, as expected in our primary
screen we identified nine such compounds. Of these initial 9
candidates, 6 compounds demonstrated dose responsive toxicity
exclusively in NSC populations. Interestingly, the compounds
Category Gene Treated NSC Untreated NSC Treated DA Neuron Untreated DA Neuron
CACNA1C 25.9 29.3 146.9 138.8
CACNA1H 122.7 87.8 268.9 220.4
doi:10.1371/journal.pone.0007155.t001
Table 1. Cont.
Figure 5. Effect of solTNFa on NSC survival. 3 concentrations of
solTNFa (0.1 mM, 1 mM and 10 mM) were added to freshly seeded NSC
cultures. Cells were evaluated up to 24 hours for signs of cell death. No
increase in cell death relative to untreated cultures was observed in the
cultures treated with solTNFa. The images taken of the cells treated
with 0.1 mM of solTNFa, are representative of data obtained for all
concentrations and are shown at (A) 1 hour, (B) 4 hours and (C)
24 hours post cytokine treatment. (D) Untreated cells are shown at
24 hours for comparison.
doi:10.1371/journal.pone.0007155.g005
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ameliorating effect on NSC survival (Fig. 2). It was surprising to
us that none of these compounds were in the expected classes of
anti cancer or anti-proliferative agents but instead included anti-
parasitic and antiarrhythmic drugs.
We chose to further investigate one of these drugs, amiodarone
HCl, which specifically killed NSCs but not dopaminergic neurons
differentiated from NSCs. Amiodarone has for decades achieved
clinical status as an effective class III antiarrhythmic drug in
cardiac patients [34,35]. Importantly, because it is already
approved for clinical use, amiodarone HCL may have clinical
applications in cell replacement therapies by selectively removing
only the unwanted undifferentiated NSCs during the pre-
transplant period.
In order to confirm that the cytotoxic effect seen in the
amiodarone HCL-treated NSCs was specific to the activity of the
drug, we first sought to determine which cellular pathways were
affected in the amiodarone HCL susceptible NSC population
relative to unaffected dopaminergic neurons receiving the same
treatment (Fig. S2). The GSEA data revealed amiodarone HCL
treated samples had significantly reduced expression of factors
involved in ion channel activity. Amiodarone is known to
specifically block ion channels, which suggests that the effect seen
in the drug treated samples is specific to amiodarone HCL activity.
To further test this, we reasoned that populations of cells with a
greater basal expression of ion channel activity mediators would be
most susceptible to drug treatment. Indeed, microarray data
confirmed that amiodarone HCL-susceptible NSCs have signifi-
cantly increased base-line expression of certain ion channels
(Table 1, SLC2A1 and CLC1A). It is tantalizing to speculate that
amiodarone HCl might also be toxic to other stem cell populations
that demonstrate increased ion channel expression relative to their
differentiated derivatives, including mesenchymal stem cells
(MSCs) and endothelial precursor cells [36], thus expanding the
utility of the automated screening assay described here.
Amiodarone has been shown to exert its cytotoxic effect via a
TNF-related signaling pathway that includes caspase-8 mediated
apoptosis [33]. Thus, we next wanted to determine whether our
assay could detect subtle changes in TNF activity in samples
treated with amiodarone HCL. Notably, downstream members of
the TNFR2 pathway were significantly augmented in the
amiodarone HCL-treated NSC population (Fig. S2). TNFR2
belongs to a class of membrane glycoprotein receptors that
specifically bind TNFa. TNFR1 is expressed on most cell types,
while TNFR2 expression is restricted to endothelial, hematopoi-
etic and some neuronal populations [37,38]. TNFa is a potent pro-
inflammatory cytokine with two biologically active forms that are
either soluble (solTNF) or membrane bound (tmTNF), and
TNFR2 is preferentially activated by tmTNF [39]. It was initially
thought that TNFa-mediated signaling downstream of TNFR1
results in apoptosis, while those downstream of TNFR2 induce
proliferation [40]. Additional work, however, revealed that in
collaboration with TNFR1, TNFa can act upon TNFR2 through
a ligand passing mechanism and trigger apoptosis [40].
These published reportsin theiraggregate support that TNFR2 can
lower the threshold of bioavailable TNFa needed to cause apoptosis
through TNFR1 thus amplifying extrinsic cell death pathways. In fact,
short term treatment of patients with amiodarone leads to a significant
decrease in the patient’s serum TNFa concentrations while
paradoxically the amiodarone toxicity is exerted through TNF-
mediated apoptotic pathways [41]. These observations are explained
by the fact that amiodarone HCL up regulates TNFR2, and TNFR2
is more dependent on ligation with tmTNF than solTNF. To test this
model, we treated amiodarone HCL-susceptible NSCs with solTNF.
If amiodarone HCL toxicity is mediated through TNFR2, and
TNFR2 is not sensitive to solTNF, then addition of solTNFa should
not be cytotoxic to the NSCs. Indeed, three doses of solTNFa
(0.1 mM, 1 mMa n d1 0mM) were tested in NSC culture for 48 hours
and no increase in cell death relative to untreated cultures was
observed (Fig. 5). This supports published reports that the addition of
solTNFa to NSC cultures actually induces proliferation and
differentiation [42,43,44]. Since TNFa i ss u c hap o t e n ti n d u c e ro f
apoptosis through TNFR1 death domain signaling, and amiodarone
treatment results in the down regulation of TNFa with concomitant
upregulation in TNFR2 signaling in NSC alone, it is possible that
amiodarone selectively kills NSCs by lowering the threshold of TNFa
required to trigger apoptosis in NSCs via upregulation of TNFR2
pathways in NSCs and not dopaminergic neurons.
Our results support our primary goal of identifying a previously
approved drug that may allow us to deplete mitotic NSCs from an
otherwise differentiated population of dopaminergic neurons, thus
ensuring their safety for use in transplantation. Importantly, this
automated screening assay allowed us to interrogate some of the
specific molecular mechanisms that may be responsible for the
targeted cytotoxic effect amiodarone HCL had on NSCs and not
cells differentiated from NSCs. While we do not purport to know
the molecular mechanisms by which amiodarone HCL leads to
the toxicity we observed in NSCs, it is notable that the results of
our automated screening, including GSEA and microarray
analysis, are all consistent with published literature that implicates
the roles of ion channels and TNFa signaling in amiodarone-
mediated cytotoxicity. This suggests that our automatic screening
assay is specifically measuring the effect amiodarone HCL has on
different populations of cells. Our methodology can also be easily
expanded to other screens in the neural system. For example, we
note that purified populations of motor neurons and oligodendro-
cytes are now readily available from hESCs and our screening
strategy can likely be extended to these cell populations as well.
In conclusion, we describe a method using hESCs and their
differentiated neural derivatives that permits the rapid screening of
clinically approved drugs for compounds that can be safely used to
selectively deplete progenitor cells from a differentiated cell
product. Importantly, this approach is adaptable for use in a
Chemistry, Manufacture and Control drug screening protocol and
may have applications in identifying lineage specific reagents, thus
providing additional evidence for the utility of stem cells in
screening and discovery paradigms.
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